Mark D. Aaron
Fondateur chez CellExSys, Inc.
Profil
Mark D.
Aaron is a Partner of Weiser LLP.
Previously, he was Senior Market Manager-Immunotherapy of Baxter Healthcare Corp.
and Senior Director-Strategic Initiatives of Targeted Genetics Corp.
Postes actifs de Mark D. Aaron
| Sociétés | Poste | Début |
|---|---|---|
CellExSys, Inc.
 CellExSys, Inc. BiotechnologyHealth Technology Part of Calyx Ventures, Inc., CellExSys, Inc. is a company that provides research and development of intellectual property in the area of cell therapy and the generation of antigen-specific T-lymphocytes. The company is based in Seattle, WA. The company was founded by David M. Schubert, Mark D. Aaron. CellExSys was acquired by Chromos Molecular Systems, Inc. from AmpliPhi Biosciences Corp. on July 28, 2004 for $3.09 million. | Fondateur | 31/10/2011 |
Anciens postes connus de Mark D. Aaron
| Sociétés | Poste | Fin |
|---|---|---|
Weiser LLP
 Weiser LLP Miscellaneous Commercial ServicesCommercial Services Weiser LLP provides accounting, auditing, tax, management information and financial advisory services to business owners and high net worth individuals. The company is located in New York, NY. | Corporate Officer/Principal | 08/04/2010 |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/12/2000 |
Baxter Healthcare Corp.
 Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Sales & Marketing | - |
Formation de Mark D. Aaron
| The Pennsylvania State University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Weiser LLP
Weiser LLP Miscellaneous Commercial ServicesCommercial Services Weiser LLP provides accounting, auditing, tax, management information and financial advisory services to business owners and high net worth individuals. The company is located in New York, NY. | Commercial Services |
CellExSys, Inc.
CellExSys, Inc. BiotechnologyHealth Technology Part of Calyx Ventures, Inc., CellExSys, Inc. is a company that provides research and development of intellectual property in the area of cell therapy and the generation of antigen-specific T-lymphocytes. The company is based in Seattle, WA. The company was founded by David M. Schubert, Mark D. Aaron. CellExSys was acquired by Chromos Molecular Systems, Inc. from AmpliPhi Biosciences Corp. on July 28, 2004 for $3.09 million. | Health Technology |
